2024
Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
Wells C, Pandey A, Moghadas S, Fitzpatrick M, Singer B, Galvani A. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States. Annals Of Internal Medicine 2024, 177: 609-617. PMID: 38527289, DOI: 10.7326/m23-2451.Peer-Reviewed Original ResearchSARS-CoV-2 vaccination campaignSARS-CoV-2Centers for Disease Control and PreventionDisease Control and PreventionSARS-CoV-2 vaccinesHealth care costsVaccine-acquired immunityFood and Drug AdministrationU.S. Food and Drug AdministrationControl and PreventionNational Institutes of HealthVaccination campaignInfluenza vaccineInitial doseInstitutes of HealthSARS-CoV-2 variantsBooster doseImmune evasionDrug AdministrationUnited StatesNotsew Orm Sands FoundationDoseHealthPopulation immunityNational InstituteImpact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Shoukat A, Bawden C, Röst G, LeBlanc J, Galvani A, Langley J, Moghadas S. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine 2024, 42: 1768-1776. PMID: 38368226, DOI: 10.1016/j.vaccine.2024.02.041.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsLong-term care homesCommunity-dwelling older adultsCanadian Immunization Research NetworkIncremental cost-effectiveness ratio valuesResidents of long-term care homesRSV diseaseOlder adultsBurden of RSV diseaseRespiratory syncytial virus diseaseNo-vaccination scenarioRSV-related hospitalisationNo vaccinesRespiratory syncytial virusVaccination programBudget impactSocietal perspectiveCost-effectiveness ratioReduction of hospitalizationInfluenza vaccineRSV seasonSyncytial virusHealth benefitsAnalysis of vaccination
2009
Optimizing Influenza Vaccine Distribution
Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. Science 2009, 325: 1705-1708. PMID: 19696313, DOI: 10.1126/science.1175570.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedCenters for Disease Control and Prevention, U.S.ChildChild, PreschoolDisease OutbreaksHealth PolicyHumansImmunization ProgramsInfantInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanMiddle AgedModels, StatisticalUnited StatesVaccinationYoung AdultConceptsOutcome measuresNovel swine-origin influenzaOptimal vaccine allocationInfluenza vaccine distributionContingent valuationSwine-origin influenzaYears of lifePublic health policyOptimal allocationEconomic costsInfluenza vaccineSeasonal influenzaInfluenza pandemicU.S. CentersVaccine allocationDisease controlMortality dataVaccine distributionHealth policyOptimal vaccinationPolicy optimizationTransmission dynamicsInfluenzaAllocationNew recommendations